Dr Snyder joined Arcutis in 2020 leading Patient Safety & Pharmacovigilance. Prior to joining us, Dr Snyder supported Safety Evaluation and Risk Management at Intercept Pharmaceuticals. Prior to this role, Dr. Snyder was at AbbVie where he lead many of the Safety Science activities for medical dermatology products on the market and in clinical development. He also supported the regulatory approval of an additional orphan indication for the treatment of a dermatologic condition in the US and Canada while working in Regulatory Affairs. During his tenure at AbbVie, Dr Snyder supported benefit-risk analyses in the oncology, infectious disease, and general medicine therapeutic areas. Dr Snyder earned his PharmD from Midwestern University’s Chicago College of Pharmacy and subsequently a MS in Biomedical Informatics at University of Chicago.